NCT02626845 - Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions

Granulomatosis With Polyangiitis (Wegener's Granulomatosis)

Interventions

DRUG

Rituximab

Standard of care induction with Rituximab: 375mg/m2 weekly x 4 weeks. Once randomized, the rituximab dose will be 1000mg IV every 4 months x 2.

OTHER

Placebo

Will be given at two time-points (week 16 and week 32) to subjects in the Placebo Arm.

Trial Locations (1)

Hospital for Special Surgery, New York